Studies show that inhibiting Gal-3 reduces microglial activation and slows the progression of AD, making Gal-3 a promising therapeutic target for neurodegenerative diseases such as Alzheimer’s [11]. This evidence concerns the gene LGALS3 and Alzheimer disease.